Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 12,222 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Healthy Volunteers, Autoimmune Disease
Interventions: LAD191, Placebo; Drug · Other
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Philadelphia, Pennsylvania • San Antonio, Texas

Conditions: Multiple Sclerosis (MS)
Interventions: Ocrelizumab, rHuPH20; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 18
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more

Conditions: Metastatic Breast Cancer, Lobular Breast Carcinoma
Interventions: Blood Specimen; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Philadelphia, Pennsylvania + 1 more

Conditions: Alzheimer's Disease
Interventions: SRA-333; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 3
States / cities: Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: dexamethasone, temsirolimus, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Las Angeles, California

Conditions: Dental Caries
Interventions: Fluoride; Drug
Lead sponsor: Indiana Nanotech, LLC; Other
Eligibility: 13 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetes Melliuts, Type 2
Interventions: Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023; Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 17
States / cities: Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more

Conditions: Multiple Myeloma, Myeloma, Disability Physical, Disabilities Multiple
Interventions: Supportive care interventions; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Interventions: Ixazomib Citrate, Lenalidomide, Questionnaire Administration; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Embolism, Thrombotic Disease
Interventions: DS-1040b, Placebo, Enoxaparin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 15
States / cities: Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more

Conditions: Lung Cancer
Interventions: Robotic-assisted lobectomy using da Vinci Surgical System, VATS (video assisted thoracic surgery), Open lobectomy; Procedure
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil, bortezomib, lenalidomide, laboratory biomarker analysis; Drug · Radiation · Procedure + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Degenerative Disc Disease
Interventions: XL TDR, Lumbar fusion surgery; Device · Other
Lead sponsor: NuVasive; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 17
States / cities: Campbell, California • Thousand Oaks, California • Durango, Colorado + 14 more

Conditions: Wrinkle
Interventions: MCD; Device
Lead sponsor: Cytrellis Biosystems, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Sacramento, California • Greenwood Village, Colorado • Miami, Florida + 3 more

Conditions: Advanced Lung Cancer
Interventions: BNT324, BNT327; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 17
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 13 more

Conditions: Multiple Sclerosis, Myasthenia Gravis, Transverse Myelitis
Interventions: Blood Draw, Cheek swab; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2031
U.S. locations: 1
States / cities: Sacramento, California

Conditions: ADHD
Interventions: SPD503-AM, SPD503-PM, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 61
States / cities: Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 53 more

Conditions: Bacterial Disease Carrier, Cystic Fibrosis
Interventions: Placebo, WRAIR-PAM-CF1; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 19
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: MS (Multiple Sclerosis), Erythema
Interventions: Warm Compress Before Injection, Cold Compress After Injection; Other
Lead sponsor: Brown, Theodore R., M.D., MPH; Individual
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Asthma
Interventions: AS MDI 90 μg, AS MDI 180 µg, Placebo MDI, Proventil 90 μg, Proventil 180 μg; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Rolling Hills Estates, California • Stockton, California • Winter Park, Florida + 7 more

Conditions: Autoimmune Diseases, Multiple Sclerosis
Interventions: LPX-TI641; Drug
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Englewood, Colorado • Weston, Florida • Scarborough, Maine

Conditions: Healthy Adults
Interventions: PF-07220060, Itraconazole, Probenecid; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Minimal (Trophic) Feeding, Full Feeding; Behavioral
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 13 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 39
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 19 more

Search by objective public record fields.

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Development and Validation of a Multi-Mineral Fluoride Mouthrinse

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

Retrospective Multi-Center Study to Compare Perioperative Outcomes for Robotic-assisted Lobectomy With Those Associated With VATS and Open Lobectomy for Lung Cancer

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)

Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Serum Auto-Antibodies in Neurological Diseases

Efficacy and Safety of SPD503 in Combination With Psychostimulants

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study)